Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | CALML3 | P27482 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544039 | 1.00 | SIGMAR1 (0.39) | SIGMAR1PIK3C3ENPP2CALML3MAOA | |
| SCHEMBL3544042 | 1.00 | SIGMAR1 (0.39) | SIGMAR1PIK3C3ENPP2CALML3MAOA | |
| SCHEMBL3538978 | 0.92 | SIGMAR1 (0.40) | SIGMAR1PIK3C3ENPP2CYP3A4CYP2D6 | |
| SCHEMBL13118371 | 0.92 | SIGMAR1 (0.40) | SIGMAR1PIK3C3ENPP2CYP3A4CYP2D6 | |
| SCHEMBL3543054 | 0.90 | SIGMAR1 (0.40) | SIGMAR1PIK3C3ENPP2CYP3A4CYP2D6 | |
| SCHEMBL3543048 | 0.90 | SIGMAR1 (0.40) | SIGMAR1PIK3C3ENPP2CYP3A4CYP2D6 | |
| SCHEMBL3543053 | 0.90 | SIGMAR1 (0.40) | SIGMAR1PIK3C3ENPP2CYP3A4CYP2D6 | |
| SCHEMBL3548440 | 0.89 | SIGMAR1 (0.42) | SIGMAR1PIK3C3ENPP2 | |
| SCHEMBL3548438 | 0.89 | SIGMAR1 (0.42) | SIGMAR1PIK3C3ENPP2 | |
| SCHEMBL3548444 | 0.89 | SIGMAR1 (0.42) | SIGMAR1PIK3C3ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854792-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-12-26 | — | — | EP | claimed |
| US-7820693-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-10-26 | — | — | US | claimed |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-01-29 | — | — | US | claimed |
| EP-1854792-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-14 | — | — | EP | claimed |
| EP-1854792-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-7820693-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1854792-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | NQO1, NR5A1, SRD5A1 | SIGMAR1 1481/4885PIK3C3 1751/4885ENPP2 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.